BOARD OF DIRECTORS
John W. Simon
Chief Executive Officer
John Simon is a co-founder and Director of Acton Pharmaceuticals and also serves as its Chief Executive Officer. Mr. Simon was previously a Vice President at Sepracor where he led the pulmonary/immunology group from 1997 to 2007, resulting in cumulative revenues of $2 billion. John is a co-founder of Forge Therapeutics, a pre-clinical stage company focused on cardiovascular disease. Earlier, John spent seven years at Forest Laboratories and has served as an advisor to health care venture capital funds and early-stage pharmaceutical and drug delivery companies. John has a BA degree from the University of Kentucky.
Daniel L. Kreisler
President and Chief Operating Officer
Daniel Kreisler is co-founder of Acton Pharmaceuticals, serves as its President and Chief Operating Officer and is a member of the Acton Board of Directors. Dan is a specialty pharmaceutical industry veteran with over 25 years of experience. Prior to Acton, Mr. Kreisler was a co-founder of JDS Pharmaceuticals, LLC, a specialty pharmaceutical company formed in 2004 where he held the position of Vice President, Business Development. In 2007, JDS was acquired by Noven Pharmaceuticals, Inc. for $125 million. Prior to co-founding Acton and JDS, Dan was co-founder of Krele Pharmaceuticals. Before that, Dan spent over 16 years at Forest Laboratories where he held positions in marketing management and business development. Dan holds a B.S. degree in Pharmacy from the University of Rhode Island.
General Partner, Sequoia Capital
Scott is a general partner at Sequoia Capital. In addition to Acton Pharmaceuticals, Scott led Sequoia's investments in four healthcare companies, AirStrip Technologies, Ameritox, eCardio and Implantable Provider Group. He also serves on the board of Merlin Securities, a leading independent prime broker. Earlier, Scott was with JPMorgan and served in various staff positions in the United States Senate. Scott has a BA in Political Science from Texas A&M University and an MBA from the Darden School of Business at the University of Virginia.